Release Date: 2023-09-14

A Current Review on Diabetes Mellitus Induced Gut Microbiota and Histological Changes

Murat Cetin Ragbetli (Author), Seda Keskin (Author)

Release Date: 2023-09-14

Recent studies have highlighted the intricate relationship between diabetes mellitus (DM) and alterations in gut microbiota composition, as well as associated histological changes. Dysbiosis, characterized by an imbalance in microbial communities, has been observed in diabetic individuals, with decreased microbial diversity and altered abundance of specific taxa such as Firmicutes and Bacteroidetes. These changes are [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Multidisciplinary Approach to Diabetes Mellitus Occurrence Mechanism
First Page15
Last Page28
DOIhttps://doi.org/10.69860/nobel.9786053359104.2
ISBN978-605-335-910-4 (PDF)
LanguageENG
Page Count14
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Recent studies have highlighted the intricate relationship between diabetes mellitus (DM) and alterations in gut microbiota composition, as well as associated histological changes. Dysbiosis, characterized by an imbalance in microbial communities, has been observed in diabetic individuals, with decreased microbial diversity and altered abundance of specific taxa such as Firmicutes and Bacteroidetes. These changes are implicated in promoting systemic inflammation, insulin resistance, and metabolic dysfunction. Concurrently, diabetic conditions influence gut barrier integrity and mucosal immunity, leading to histological alterations such as increased intestinal permeability and inflammation. The bidirectional interactions between gut microbiota and host metabolism underscore the potential of targeting the gut microbiome as a therapeutic approach in managing DM and its complications. Further research into the mechanistic links between gut microbiota dysbiosis, histological changes, and metabolic outcomes is crucial for developing targeted interventions to improve diabetic outcomes.

Murat Cetin Ragbetli (Author)
Professor, Karamanoglu Mehmetbey University
https://orcid.org/0000-0002-8189-264X

Seda Keskin (Author)
Research Assistant, Van Yuzuncu Yil University
https://orcid.org/0000-0002-4726-982X

  • Baynes HW. Classifi cation, pathophysiology, diagnosis and management of diabetes mellitus. J diabetes metab. 2015;6(5):1-9.

  • DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. The Lancet. 2018;391(10138):2449-62.

  • Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-Davis EJ, et al. Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocrine reviews. 2018;39(5):629-63.

  • Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63(9):1513-21.

  • Burrows MP, Volchkov P, Kobayashi KS, Chervonsky AV. Microbiota regulates type 1 diabetes through Toll-like receptors. Proceedings of the Nati

  • Zhang L, Zhang T, Sun J, Huang Y, Liu T, Ye Z, et al. Calorie restriction ameliorates hyperglycemia, modulates the disordered gut microbiota, and mitigate onal Academy of Sciences. 2015;112(32):9973-7. s metabolic endotoxemia and infl ammation in type 2 diabetic rats. Journal of Endocrinological Investigation. 2023;46(4):699-711.

  • Dao L, Choi S, Freeby M. Type 2 diabetes mellitus and cognitive function: understanding the connections. Current Opinion in Endocrinology & Diabetes and Obesity. 2023;30(1):7-13.

  • Lima JE, Moreira NC, Sakamoto-Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutation Research/ Genetic Toxicology and Environmental Mutagenesis. 2022;874:503437.

  • Ansari MHR, Saher S, Parveen R, Khan W, Khan IA, Ahmad S. Role of gut microbiota metabolism and biotransformation on dietary natural products to human health implications with special reference to biochemoinformatics approach. Journal of Traditional and Complementary Medicine. 2023;13(2):150-60.

  • Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. The Journal of clinical investigation. 2011;121(6):2126-32.

  • Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174-82.

  • Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, shortchain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839-49.

  • Haider K, Rehman K, Akash MSH. Impaired lipid metabolism in metabolic disorders. Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies. 2021:83-94.

  • Rehman K, Akash MSH. Mechanisms of infl ammatory responses and development of insulin resistance: how are they interlinked? Journal of biomedical science. 2016;23(1):1-18.

  • Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152(4):673-84.

  • Jaber FA, James JW. Early Prediction of Diabetic Using Data Mining. SN Computer Science. 2023;4(2):169.

  • Shah MK, Khan FN, Ali MK. Diabetes Management in the United States. The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues. 2023:309-28.

  • Bak JC, Serné EH, de Valk HW, Valk NK, Kramer MH, Nieuwdorp M, et al. Gender gaps in type 1 diabetes care. Acta Diabetologica. 2023:1-10.

  • Meneghini LF. Medical Management of Type 2 Diabetes: American Diabetes Association; 2023.

  • Rodriguez-Saldana J. The diabetes textbook: Clinical principles, patient management and public health issues: Springer Nature; 2023.

  • McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nature reviews Disease primers. 2019;5(1):47.

  • Piccioni A, Rosa F, Mannucci S, Manca F, Merra G, Chiloiro S, et al. Gut Microbiota, LADA, and Type 1 Diabetes Mellitus: An Evolving Relationship. Biomedicines. 2023;11(3):707.

  • Bhattamisra SK, Siang TC, Rong CY, Annan NC, Sean EH, Xi LW, et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas-an update. Current diabetes reviews. 2019;15(5):382-94.

  • Alington K, Cummings MH. Pancreatic exocrine dysfunction: common in type 3c diabetes, but don’t forget types 1 and 2 diabetes mellitus. Practical Diabetes. 2017;34(6):200-4a.

  • Tosur M, Philipson LH. Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY). Journal of Diabetes Investigation. 2022;13(9):1465-71.

  • Liu J, Xiao X, Zhang Q, Yu M. Insights from basic adjunctive examinations of GCK-MODY, HNF1AMODY, and type 2 diabetes: A systemic review and meta-analysis. Journal of Diabetes. 2023.

  • C, Moreira PI. Metabolic defects shared by Alzheimer’s disease and diabetes: A focus on mitochondria. Current Opinion in Neurobiology. 2023;79:102694.

  • Sanchez-Rangel E, Deajon-Jackson J, Hwang JJ. Pathophysiology and management of hypoglycemia in diabetes. Annals of the New York Academy of Sciences. 2022.

  • Tachibana M, Imagawa A. Type 1 diabetes related to immune checkpoint inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism. 2022:101657.

  • Rossing P. Diabetic Nephropathy in Type 1 Diabetes Mellitus. Blood Pressure Disorders in Diabetes Mellitus: Springer; 2023. p. 231-42.

  • Rathod S. Novel insights into the immunotherapy-based treatment strategy for autoimmune type 1 diabetes. Diabetology. 2022;3(1):79-96.

  • Martin A, Mick GJ, Choat HM, Lunsford AA, Tse HM, McGwin Jr GG, et al. A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes. Nature Communications. 2022;13(1):7928.

  • Doliba NM, Rozo AV, Roman J, Qin W, Traum D, Gao L, et al. α Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibody–positive individuals. The Journal of Clinical Investigation. 2022;132(11).

  • Kawamori D, Sasaki S. Newly discovered knowledge pertaining to glucagon and its clinical applications. Journal of Diabetes Investigation. 2023.

  • Kalwat MA, Rodrigues-dos-Santos K, Binns DD, Wei S, Zhou A, Evans MR, et al. Small molecule glucagon release inhibitors with activity in human islets. Frontiers in Endocrinology. 2023;14.

  • Sanches JM, Zhao LN, Salehi A, Wollheim CB, Kaldis P. Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. The FEBS Journal. 2023;290(3):620-48.

  • Ma Q, Li Y, Li P, Wang M, Wang J, Tang Z, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal fl ora. Biomedicine & Pharmacotherapy. 2019;117:109138.

  • Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine. 2022.

  • Tong Y, Xu S, Huang L, Chen C. Obesity and insulin resistance: Pathophysiology and treatment. Drug Discovery Today. 2022;27(3):822-30.

  • Apostolova N, Vezza T, Muntané J, Rocha M, Victor VM. Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets. Antioxidants and Redox Signaling. 2023(ja).

  • Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, et al. The Role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. International Journal of Molecular Sciences. 2022;23(8):4334.

  • Bhat N, Mani A. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients. 2023;15(10):2323.

  • Hulett NA, Scalzo RL, Reusch JE. Glucose uptake by skeletal muscle within the contexts of type 2 diabetes and exercise: An integrated approach. Nutrients. 2022;14(3):647.

  • Narasimhan A, Flores RR, Camell CD, Bernlohr DA, Robbins PD, Niedernhofer LJ. Cellular Senescence in Obesity and Associated Complications: a New Therapeutic Target. Current diabetes reports. 2022;22(11):537-48.

  • Li K, Bian J, Xiao Y, Wang D, Han L, He C, et al. Changes in Pancreatic Senescence Mediate Pancreatic Diseases. International Journal of Molecular Sciences. 2023;24(4):3513.

  • Jain C, Ansarullah, Bilekova S, Lickert H. Targeting pancreatic β cells for diabetes treatment. Nature Metabolism. 2022;4(9):1097-108.

  • Khamis AM. Pathophysiology, Diagnostic Criteria, and Approaches to Type 2 Diabetes Remission. Cureus. 2023;15(1).

  • Carrizales-Sánchez AK, Tamez-Rivera O, Rodríguez-Gutiérrez NA, Elizondo-Montemayor L, Gradilla- Hernández MS, García-Rivas G, et al. Characterization of gut microbiota associated with metabolic syndrome and type-2 diabetes mellitus in Mexican pediatric subjects. BMC pediatrics. 2023;23(1):1-13.

  • Bagyánszki M, Bódi N. Key elements determining the intestinal region-specifi c environment of enteric neurons in type 1 diabetes. World Journal of Gastroenterology. 2023;29(18):2704-16.

  • Ito A, Matsui Y, Takeshita M, Katashima M, Goto C, Kuriki K. Gut microbiota-mediated associations of green tea and catechin intakes with glucose metabolism in individuals without type 2 diabetes mellitus: a four-season observational study with mediation analysis. Archives of Microbiology. 2023;205(5):191.

  • Chen L, Liu B, Ren L, Du H, Fei C, Qian C, et al. High-fi ber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients. Frontiers in Cellular and Infection Microbiology. 2023;13:66.

  • Qi Y, Wang X. The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans. Nutrients. 2023;15(4):922.

  • Longo S, Rizza S, Federici M. Microbiota-gut-brain axis: Relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Acta Diabetologica. 2023:1-11.

  • Devi MB, Sarma HK, Mukherjee AK, Khan MR. Mechanistic Insights into Immune-Microbiota Interactions and Preventive Role of Probiotics Against Autoimmune Diabetes Mellitus. Probiotics and Antimicrobial Proteins. 2023:1-18.

  • Safari-Alighiarloo N, Emami Z, Rezaei-Tavirani M, Alaei-Shahmiri F, Razavi S. Gut Microbiota and Their Associated Metabolites in Diabetes: A Cross Talk Between Host and Microbes—A Review. Metabolic Syndrome and Related Disorders. 2023;21(1):3-15.

  • Du L, Li Q, Yi H, Kuang T, Tang Y, Fan G. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. Biomedicine & Pharmacotherapy. 2022;149:112839.

  • Craciun C-I, Neag M-A, Catinean A, Mitre A-O, Rusu A, Bala C, et al. The relationships between gut microbiota and diabetes mellitus, and treatments for diabetes mellitus. Biomedicines. 2022;10(2):308.

  • Bielka W, Przezak A, Pawlik A. The role of the gut microbiota in the pathogenesis of diabetes. International journal of molecular sciences. 2022;23(1):480.

  • Ye J, Wu Z, Zhao Y, Zhang S, Liu W, Su Y. Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: Advanced research-based review. Frontiers in Microbiology. 2022;13:1029890.

  • Schupack DA, Mars RA, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nature Reviews Gastroenterology & Hepatology. 2022;19(1):7- 25.

  • Barko P, McMichael M, Swanson KS, Williams DA. The gastrointestinal microbiome: a review. Journal of veterinary internal medicine. 2018;32(1):9-25.

  • Yang L, Yuan T-j, Wan Y, Li W-w, Liu C, Jiang S, et al. Quorum sensing: a new perspective to reveal the interaction between gut microbiota and host. Future Microbiology. 2022;17(4):293-309.

  • Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cellular and Molecular Life Sciences. 2019;76:473-93.

  • Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.

  • Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology. 2014;146(6):1449-58.

  • Ye D, Huang J, Wu J, Xie K, Gao X, Yan K, et al. Integrative metagenomic and metabolomic analyses reveal gut microbiota-derived multiple hits connected to development of gestational diabetes mellitus in humans. Gut Microbes. 2023;15(1):2154552.

  • Sowmiya T, Silambanan S. Association of Gut Microbiota and Diabetes Mellitus. Current Diabetes Reviews. 2023;19(7):15-8.

  • Bajinka O, Tan Y, Darboe A, Ighaede-Edwards IG, Abdelhalim KA. The gut microbiota pathway mechanisms of diabetes. AMB Express. 2023;13(1):1-10.

  • Tang C, Bao T, Zhang Q, Qi H, Huang Y, Zhang B, et al. Clinical potential and mechanistic insights of mulberry (Morus alba L.) leaves in managing type 2 diabetes mellitus: Focusing on gut microbiota, infl ammation, and metabolism. Journal of Ethnopharmacology. 2023:116143.

  • Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.

  • Larsen PE, Dai Y. Metabolome of human gut microbiome is predictive of host dysbiosis. Gigascience. 2015;4(1):s13742-015-0084-3.

  • Ratiner K, Fachler-Sharp T, Elinav E. Small Intestinal Microbiota Oscillations, Host Effects and Regulation— A Zoom into Three Key Effector Molecules. Biology. 2023;12(1):142.

  • Bamba S, Imai T, Sasaki M, Ohno M, Yoshida S, Nishida A, et al. Altered gut microbiota in patients with small intestinal bacterial overgrowth. Journal of gastroenterology and hepatology. 2023;38(1):61-9.

  • Ayob N, Muhammad Nawawi KN, Mohamad Nor MH, Raja Ali RA, Ahmad HF, Oon SF, et al. The Effects of Probiotics on Small Intestinal Microbiota Composition, Infl ammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines. 2023;11(2):640.

  • Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54:3055-61.

  • MV, Al-Obaide MA, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates infl ammation in type 2 diabetic patients with chronic kidney disease. Experimental and therapeutic medicine. 2019;18(5):3461-9.

  • GJMG, de Assis Costa J, Alfenas RdCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism. 2017;68:133-44.

  • Koch L. Tissue bacteria predict diabetes onset. Nature Reviews Endocrinology. 2012;8(1):3-.

  • Zoetendal EG, Raes J, Van Den Bogert B, Arumugam M, Booijink CC, Troost FJ, et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. The ISME journal. 2012;6(7):1415-26.

  • Graham S, Courtois P, Malaisse W, Rozing J, Scott FW, Mowat AMI. Enteropathy precedes type 1 diabetes in the BB rat. Gut. 2004;53(10):1437-44.

  • Knauf C, Abot A, Wemelle E, Cani PD. Targeting the enteric nervous system to treat metabolic disorders?“Enterosynes” as therapeutic gut factors. Neuroendocrinology. 2020;110(1-2):139-46.

  • Zavaleta MJC, Yovera JGG, Marreros DMM, Robles LdPR, Taype KRP, Gálvez KNS, et al. Diabetic gastroenteropathy: An underdiagnosed complication. World Journal of Diabetes. 2021;12(6):794.

  • Niesler B, Kuerten S, Demir IE, Schäfer K-H. Disorders of the enteric nervous system—a holistic view. Nature reviews Gastroenterology & hepatology. 2021;18(6):393-410.

  • Mesgari-Abbasi M, Ghaderi S, Khordadmehr M, Nofouzi K, Tayefi -Nasrabadi H, McIntyre G. Enteroprotective effect of Tsukamurella inchonensis on streptozotocin induced type 1 diabetic rats. Turkish Journal of Biochemistry. 2019;44(5):683-91.

  • Zheng P, Li Z, Zhou Z. Gut microbiome in type 1 diabetes: A comprehensive review. Diabetes Metab Res Rev. 2018;34(7):e3043.

  • Meldgaard T, Olesen SS, Farmer AD, Krogh K, Wendel AA, Brock B, et al. Diabetic enteropathy: from molecule to mechanism-based treatment. Journal of diabetes research. 2018;2018.

  • Singla S, Kumar V, Jena G. 3-aminobenzamide protects against colitis associated diabetes mellitus in male BALB/c mice: Role of PARP-1, NLRP3, SIRT-1, AMPK. Biochimie. 2023;211:96-109.

  • Costa CJ, Cohen MW, Goldberg DC, Mellado W, Willis DE. Nicotinamide Riboside Improves Enteric Neuropathy in Streptozocin-Induced Diabetic Rats Through Myenteric Plexus Neuroprotection. Digestive Diseases and Sciences. 2023:1-12.

  • Barta BP, Onhausz B, Doghmi AA, Szalai Z, Balázs J, Bagyánszki M, et al. Gut region-specifi c TNFR expression: TNFR2 is more affected than TNFR1 in duodenal myenteric ganglia of diabetic rats. World Journal of Diabetes. 2023;14(1):48-61.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!